Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03628040
Other study ID # 112452
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 1, 2019
Est. completion date January 1, 2021

Study information

Verified date June 2019
Source Lawson Health Research Institute
Contact Cheng Lin, FRCPC
Phone 5196858500
Email cheng.lin@lhsc.on.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Video-Assisted Thoracoscopic Surgery (VATS) is a minimally invasive surgery that utilizes camera based scopes and specialized instruments through keyhole sized ports to remove lesions in the thoracic cavity. Despite reduced surgical trauma compared to the traditional thoracotomy approach, patients continued to experience moderate to severe postoperative pain. Pain medication such as opioids is commonly utilized for postoperative pain control but is associated with side effects. The use of nerve blocks, such as the recently described erector spinae plane block (ESPB) has been shown in case reports to reduce pain and thus has the potential to improve patient recovery and decrease the risk of pulmonary complication. This study aims to investigate the analgesic effect of ESPB in managing pain following VATS.


Description:

VATS is a minimally invasive surgical technique to remove intrathoracic lesions. Using a camera based scope and specifically designed instruments, the surgery can be initiated with three "key-hole" sized incisions. At the end of the surgery, an incision is enlarged to allow removal of surgical specimen. Chest tubes are inserted at the end of procedure and sutured in between the ribs.

While acute pain after VATS is less than the traditional thoracotomy, patients still experience moderate amount of pain within the first 24 hours. Source of pain may be from diaphragm irritation, surgical incisions and chest tubes. Because of its origin on the chest wall, pain from VATS worsens with breathing. When pain is poorly controlled, it will lead to a shallow breathing pattern called "splinting" and this can progress to respiratory distress or failure. Given the high incidence of smoking history in this patient population, many would have presented with poor baseline respiratory function. Therefore, it is important to provide good pain control to allow deep breathing and cough to reduce respiratory complications[1][2].

Despite the smaller incisions, the incidence of chronic post-surgical pain (CPSP) after VATS is surprisingly similar to thoracotomy. The mechanism may be due to nerve compression by the trocar, an instrument inserted between the ribs to allow smooth manipulation of camera and surgical instruments in the thoracic cavity. Additionally, poorly controlled acute pain has also been postulated to lead to the development of CPSP, further emphasizing the importance of good analgesia[1].

Many regional analgesia techniques have been tried to improve postoperative analgesia. Thoracic epidural analgesia (TEA) remains the gold standard of pain control after thoracic surgery. Although it provides superior analgesia, its use is hindered by the rare but serious complication of epidural hematoma and abscess which may cause paralysis. Further, pain from VATS tends to be short-lived (less than 24 hours), making the risk to benefit ratio less ideal for TEA. An alternative to TEA is paravertebral block (PVB). Compared to TEA, it causes less hypotension and hematoma or abscess at the paravertebral space may be less consequential. Nevertheless, PVB is a deep block and is technically demanding which limits its wide adoption[3].

Erector spinae plane block (ESPB) is a novel nerve block that has been used for analgesia for surgeries of the chest and abdominal wall. Using a bony structure, the transverse process, as the end point, the block needle is very unlikely to cause injury to vital structures as is possible with TEA or PVB (for examples, the spinal cord, lungs and blood vessels). It is also technically easy to perform. ESPB has only been reported in case series but so far, no adverse events such as hypotension, hematoma or infection has been reported. ESPB has also showed promise in managing CPSP after thoracic surgery in a small case series[4].

Given its safety, ease of performance and efficacy, the study aims to study the analgesic efficacy of ESPB in addition to systemic analgesia compared to systemic analgesia alone in patients undergoing VATS. The hypothesis is that ESPB and systemic analgesia will provide better analgesia when compared to systemic analgesia alone.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 82
Est. completion date January 1, 2021
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult patients

2. Scheduled for an elective VATS

3. American Society of Anesthesiologists (ASA) physical status I to III

Exclusion Criteria:

1. Age < 18

2. BMI > 40

3. Patient refusal or inability to provide consent

4. Chronic pain conditions

5. Daily opioid use > 60 mg of oral morphine equivalents

6. Cognitive or psychiatric condition that makes it challenge to assess pain

7. Conversion to open thoracotomy

8. Allergy to any of the drugs used in this study

9. Contraindication to nerve blocks such as infection, severe coagulopathy or pre-existing neuropathy

10. Significant systemic cardiac, respiratory, hepatic or renal diseases

11. Postoperative admission to intensive care unit

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ropivacaine Injection [Naropin]
Ropivacaine will be injected in the erector spinae plane
Normal saline
Normal saline will be injected in the erector spinae plane

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Lawson Health Research Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Opioid consumption in IV morphine equivalents All source of opioid First postoperative 24 hour
Secondary Opioid consumption in IV morphine equivalents All source of opioid Second postoperative 24 hours
Secondary Area under curve of pain score 0 - 10 numeric rating scale for pain (0 minimal pain and 10 worst pain ever) First postoperative 24 hour
Secondary Area under curve of pain score 0 - 10 numeric rating scale for pain (0 minimal pain and 10 worst pain ever) Second postoperative 24 hour
Secondary Post-anesthetic recovery length of stay In minutes up to 12 hours
Secondary Hospital length of stay in hours Up to 1 week
Secondary Incidence of nausea patient reported sensation of nausea related to opioid intake Up to 1 week
Secondary Incidence of vomiting nurse recorded incidence of vomiting related to opioid intake Up to 1 week
Secondary Incidence of drowsiness lightheadedness, drowsiness reported by patient related to opioid intake Up to 1 week
Secondary Incidence of pruritus new onset of pruritus related to opioid intake Up to 1 week
Secondary Incidence of infection at block injection site defined as redness, swelling, tenderness and/or prurulent discharge Up to 1 week
Secondary Incidence of symptomatic hematoma at block injection site collection of blood confirmed by ultrasound Up to 1 week
Secondary Incidence of paresthesia in the area covered by block paresthesia, decreased sensation thought to related to block Up to 1 week
Secondary Incidence of hypoxia hypoxia (SaO2 < 90%) despite > 5 L oxygen during the first 24 hours
Secondary Incidence of mechanical ventilation requiring re-intubation during the first 24 hours
Secondary Incidence of tachypnea Respiratory rate more than 30 for more than 2 hours during the first 24 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A